Five Serologic Tests Evaluated for Threadworm Infection Follow-Up
By LabMedica International staff writers Posted on 25 Feb 2015 |
Image: Adult female of Strongyloides stercoralis collected in bronchial fluid of a patient with disseminated disease (Photo courtesy of Sacro Cuore Hospital).
Traditional fecal-based methods have poor sensitivity for the detection of Strongyloides stercoralis, therefore are inadequate for post-treatment evaluation of infected patients who should be carefully monitored to exclude the persistence of the infection.
The performance of the five serological tests has been compared for the follow up of patients after treatment, who were infected with S. stercoralis or threadworm, in order to identify if antibody decline could be used a surrogate marker for cure, in addition to negative stools.
Scientists at the Center for Tropical Diseases, Sacro Cuore Hospital (CTD; Verona, Italy) and an international team carried out retrospective study on archived, anonymized sera available at the CTD. Samples were classified according to a composite reference standard, a procedure used for evaluation of diagnostic tests when there is no gold standard: a) positive: positive fecal tests and/or at least 3/5 positive serologic tests; b) negative: negative fecal tests and less than three positive results out of the five serologic tests.
The samples were tested with two commercially-available enzyme-linked immunosorbent assays (ELISA) for Strongyloides (IVD Research; Carlsbad, CA, USA, and Bordier Affinity Products; Crissier, Switzerland), and three noncommercial tests: immunofluorescence antibody test (IFAT), recombinant Strongyloides antigen (NIE) enzyme-linked immunosorbent assay (NIE-ELISA), and the NIE- luciferase immunoprecipitation systems (NIE-LIPS).
A high proportion of samples demonstrated for each test a seroreversion or a relevant decline in optical density/relative light units halved or decreases of at least two titers for IFAT at follow up. The results confirmed by the linear mixed effects model that showed a trend to seroreversion over time for all tests. In particular, IVD-ELISA where almost 90% samples demonstrated relevant decline and almost 87% of IFAT had the best performances. Considering only samples with a complete negativization, NIE-ELISA showed the best performance with 72.5% seroreversion.
The authors that concluded that each of the serology tests considered can be used for monitoring patients who received a treatment for S. stercoralis infection. Serology, in combination with fecal-based methods, should be used as the preferred tool for the follow up. Validation of polymerase chain reaction (PCR) techniques for the follow up might be a useful support for situations of uncertainty such as patients with serology values that do not seem to decrease over time. The study was published on February 10, 2015, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Center for Tropical Diseases
IVD Research
Bordier Affinity Products
The performance of the five serological tests has been compared for the follow up of patients after treatment, who were infected with S. stercoralis or threadworm, in order to identify if antibody decline could be used a surrogate marker for cure, in addition to negative stools.
Scientists at the Center for Tropical Diseases, Sacro Cuore Hospital (CTD; Verona, Italy) and an international team carried out retrospective study on archived, anonymized sera available at the CTD. Samples were classified according to a composite reference standard, a procedure used for evaluation of diagnostic tests when there is no gold standard: a) positive: positive fecal tests and/or at least 3/5 positive serologic tests; b) negative: negative fecal tests and less than three positive results out of the five serologic tests.
The samples were tested with two commercially-available enzyme-linked immunosorbent assays (ELISA) for Strongyloides (IVD Research; Carlsbad, CA, USA, and Bordier Affinity Products; Crissier, Switzerland), and three noncommercial tests: immunofluorescence antibody test (IFAT), recombinant Strongyloides antigen (NIE) enzyme-linked immunosorbent assay (NIE-ELISA), and the NIE- luciferase immunoprecipitation systems (NIE-LIPS).
A high proportion of samples demonstrated for each test a seroreversion or a relevant decline in optical density/relative light units halved or decreases of at least two titers for IFAT at follow up. The results confirmed by the linear mixed effects model that showed a trend to seroreversion over time for all tests. In particular, IVD-ELISA where almost 90% samples demonstrated relevant decline and almost 87% of IFAT had the best performances. Considering only samples with a complete negativization, NIE-ELISA showed the best performance with 72.5% seroreversion.
The authors that concluded that each of the serology tests considered can be used for monitoring patients who received a treatment for S. stercoralis infection. Serology, in combination with fecal-based methods, should be used as the preferred tool for the follow up. Validation of polymerase chain reaction (PCR) techniques for the follow up might be a useful support for situations of uncertainty such as patients with serology values that do not seem to decrease over time. The study was published on February 10, 2015, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Center for Tropical Diseases
IVD Research
Bordier Affinity Products
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form